Skip to main content

Table 5 Association between waiting time and the change in SF-12v2 mental component scale from baseline to the 6-month follow-up, for the overall sample and by main rheumatic condition

From: The association between waiting time and multidisciplinary pain treatment outcomes in patients with rheumatic conditions

 

MCS at baseline, Mean (SD)

MCS at 6 months, Mean (SD)

GEE models

Unadj. p value a

Unadj. change from baseline to 6 months, EMM (95% CI)

Adj.

p value a,b

Adj. change from baseline to 6 months, EMM b (95% CI)

Overall sample (n)

3210

1940

0.000

 

0.001

 

 Total

29.1 (11.4)

31.6 (12.5)

    

 < 2 months

29.9 (11.7)

33.5 (13.0)

 

3.6 [2.4, 4.9]

 

3.7 [2.3, 5.0]

 2–6 months

28.7 (11.5)

30.5 (12.6)

 

1.4 [0.4, 2.4]

 

1.5 [0.3, 2.6]

 > 6 months

28.8 (11.0)

31.0 (11.8)

 

1.9 [1.0, 2.8]

 

2.0 [1.0, 3.0]

Osteoarthritis (n)

665

395

0.112

 

0.308

 

 Total

31.4 (11.3)

33.5 (12.3)

    

 < 2 months

30.7 (11.4)

33.7 (12.1)

 

3.4 [0.7, 6.2]

 

3.2 [0.3, 6.2]

 2–6 months

31.5 (11.9)

33.4 (13.3)

 

1.1 [−1.2, 3.4]

 

1.6 [−1.3, 4.4]

 > 6 months

32.0 (10.6)

33.5 (11.5)

 

1.2 [−0.9, 3.29]

 

1.5 [−0.8, 3.7]

Fibromyalgia (n)

670

358

0.021

 

0.012

 

 Total

27.2 (11.0)

29.0 (12.6)

    

 < 2 months

27.9 (10.5)

32.7 (12.2)

 

4.9 [1.7, 8.1]

 

4.9 [1.5, 8.3]

 2–6 months

27.7 (11.8)

28.9 (13.7)

 

1.6 [−0.6, 3.8]

 

0.9 [−1.1, 3.0]

 > 6 months

26.3 (10.5)

27.1 (11.4)

 

1.3 [−0.6, 3.21]

 

1.0 [−1.0, 2.9]

  1. MCS SF-12v2 Mental component scale, SD standard deviation, GEE generalized estimating equations, EMM estimated marginal means, 95% CI 95% confidence interval
  2. a Time X group effect p value
  3. b Adjusted for age, sex, pain duration, number of comorbidities and income